Alarar Capital Group is pleased to announce that Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC, CYCCP), a clinical-stage biopharmaceutical company, has successfully completed a $1 million private placement offering of its convertible Series E Preferred Stock to accredited investors. The transaction closed on March 21, 2025, and was conducted without the involvement of a placement agent, broker, or dealer.

The net proceeds of the offering will be used for working capital and general corporate purposes. Based on current operating assumptions, the financing is expected to extend Cyclacel’s cash runway into the third quarter of 2025.

Each share of Series E Preferred Stock is convertible into 110 shares of Cyclacel’s common stock, subject to stockholder approval in accordance with Nasdaq listing rules. The Preferred Stock also entitles holders to participate in any dividends declared on the Company’s common stock on an as-converted basis.

The securities were issued under Regulation S of the Securities Act of 1933, as amended, and are not registered under U.S. securities laws. As such, they may not be offered or sold in the United States absent an effective registration statement or an applicable exemption.

Alarar Capital Group served as financial advisor to Cyclacel in this transaction.

Rimon P.C. served as legal counsel to Cyclacel.

Nigel Wong, Vice President at Alarar Capital Group, commented, “We are proud to have supported Cyclacel in securing this timely capital raise. This strategic financing reinforces Cyclacel’s operational runway and supports the advancement of its innovative oncology pipeline. We look forward to continuing our partnership as the company drives forward its mission to develop life-changing cancer therapies.”

About Cyclacel Pharmaceuticals, Inc.

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation, and mitosis biology. Its pipeline includes fadraciclib, a CDK2/9 inhibitor, and plogosertib, a PLK1 inhibitor, for the treatment of both solid tumors and hematological malignancies.

About Alarar Capital Group

Alarar Capital Group is a globally based investment bank and management consultancy firm, specializing in bridging Asia and the West. Our services encompass a full spectrum of financial solutions, including IPOs, M&A, financing, venture capital, and SPACs. Alarar Capital Group also includes an independent consulting division dedicated to addressing the unique challenges faced by companies operating across both Asian and Western markets. Headquartered in Hong Kong, with offices across Mainland China, the USA, Malaysia, Indonesia, Vietnam, India, Sweden, and the UAE, we are well-positioned to provide cross-border financial and advisory services.

Our commitment to anticipating market trends and delivering client-centered solutions has earned Alarar Capital Group the Frost & Sullivan 2024 Company of the Year Award in the Asian mid-market investment advisory sector.

For more information or any questions, please contact:

Nigel Wong
Vice President
[email protected]

For media inquiries, please contact:

Anna Sahlberg Carlsson
Marketing Manager
[email protected]